WO2006069200A3 - Group b streptococcus - Google Patents

Group b streptococcus Download PDF

Info

Publication number
WO2006069200A3
WO2006069200A3 PCT/US2005/046491 US2005046491W WO2006069200A3 WO 2006069200 A3 WO2006069200 A3 WO 2006069200A3 US 2005046491 W US2005046491 W US 2005046491W WO 2006069200 A3 WO2006069200 A3 WO 2006069200A3
Authority
WO
WIPO (PCT)
Prior art keywords
streptococcus
group
vaccines
antibiotics
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/046491
Other languages
French (fr)
Other versions
WO2006069200A2 (en
Inventor
Herve Tettelin
Vega Masignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002591510A priority Critical patent/CA2591510A1/en
Priority to EP05857170A priority patent/EP1828231A2/en
Priority to AU2005319174A priority patent/AU2005319174A1/en
Priority to JP2007548453A priority patent/JP2008525033A/en
Priority to NZ555934A priority patent/NZ555934A/en
Priority to US11/793,435 priority patent/US20090104218A1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to MX2007007033A priority patent/MX2007007033A/en
Publication of WO2006069200A2 publication Critical patent/WO2006069200A2/en
Publication of WO2006069200A3 publication Critical patent/WO2006069200A3/en
Priority to IL183830A priority patent/IL183830A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Polypeptides and nucleic acids from Streptococcus agalactiae which can be used in the development of vaccines, for diagnostic purposes, and as targets for antibiotics.
PCT/US2005/046491 2004-12-22 2005-12-21 Group b streptococcus Ceased WO2006069200A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP05857170A EP1828231A2 (en) 2004-12-22 2005-12-21 Group b streptococcus
AU2005319174A AU2005319174A1 (en) 2004-12-22 2005-12-21 Group B Streptococcus
JP2007548453A JP2008525033A (en) 2004-12-22 2005-12-21 Group B Streptococcus
NZ555934A NZ555934A (en) 2004-12-22 2005-12-21 Polypeptides from the Group B Streptococcus (GBS) and uses thereof in treating and detecting GBS disease or infection
US11/793,435 US20090104218A1 (en) 2004-12-22 2005-12-21 Group B Streptococcus
CA002591510A CA2591510A1 (en) 2004-12-22 2005-12-21 Group b streptococcus
MX2007007033A MX2007007033A (en) 2004-12-22 2005-12-21 Group b streptococcus.
IL183830A IL183830A0 (en) 2004-12-22 2007-06-11 Group b streptococcus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63894304P 2004-12-22 2004-12-22
US60/638,943 2004-12-22
US64043804P 2004-12-30 2004-12-30
US60/640,438 2004-12-30

Publications (2)

Publication Number Publication Date
WO2006069200A2 WO2006069200A2 (en) 2006-06-29
WO2006069200A3 true WO2006069200A3 (en) 2007-03-01

Family

ID=36602309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046491 Ceased WO2006069200A2 (en) 2004-12-22 2005-12-21 Group b streptococcus

Country Status (8)

Country Link
US (1) US20090104218A1 (en)
EP (1) EP1828231A2 (en)
JP (1) JP2008525033A (en)
AU (1) AU2005319174A1 (en)
CA (1) CA2591510A1 (en)
IL (1) IL183830A0 (en)
MX (1) MX2007007033A (en)
WO (1) WO2006069200A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101066447A (en) 1998-12-22 2007-11-07 微科学有限公司 Group b streptococcus proteins, and their use
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
ES2505695T3 (en) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Immunogenic compositions for Streptococcus pyogenes
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
EP1801235A1 (en) 2005-12-20 2007-06-27 Institut Pasteur Rapid detection of the "high virulent" ST-17 clone of Group B streptococcus
US20100261618A1 (en) * 2006-06-19 2010-10-14 Sonia Escaich Identification of genes implicated in the virulence of streptococcus agalactiae
WO2009027768A2 (en) * 2006-07-26 2009-03-05 Novartis Ag Immunogenic compositions for gram positive bacteria
EP2135877A1 (en) * 2008-06-19 2009-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Marker of steptococcus anginosus/Streptococcus constellatus (Moac) and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
ITMI20090946A1 (en) 2009-05-28 2010-11-29 Novartis Ag EXPRESSION OF RECOMBINANT PROTEINS
RU2580299C2 (en) 2009-06-29 2016-04-10 Дженосеа Биосайенсиз, Инк. Streptococcus pneumoniae vaccines and compositions
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012100233A1 (en) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
KR20140026372A (en) * 2011-02-02 2014-03-05 이무노퓨처 아이앤씨. Drug delivery material capable of passing through blood-brain barrier, and peptide and use thereof
EP2557424A1 (en) 2011-08-11 2013-02-13 InGen Biosciences Method for diagnosing Streptococcus, Enterococcus and Pepstostreptococcus genera infections
WO2013124473A1 (en) * 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
EP2831250B1 (en) * 2012-03-30 2021-11-24 DuPont US Holding, LLC Enzymes useful for peracid production
RU2015106791A (en) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са IMMUNOGENIC COMPOSITIONS
EP3021864A1 (en) * 2013-07-16 2016-05-25 Université de Lausanne Bacterial lysins and uses thereof
MX2017001638A (en) * 2014-08-05 2017-04-27 Glaxosmithkline Biologicals Sa Carrier molecule for antigens.
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
WO2018204153A1 (en) * 2017-05-02 2018-11-08 Venomyx, Inc. Composition and methods for treating snake envenomation
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
PL239045B1 (en) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitope specific for infectious Streptococcus agalactiae and the method of detecting infection of the patient with Streptococcus agalactiae
AU2019286648B2 (en) * 2018-06-13 2023-11-23 Gen-Probe Incorporated Compositions and methods for detecting group B Streptococcus nucleic acid
BR112021002250A2 (en) 2018-08-06 2021-07-20 Medikine, Inc. IL-2 receptor binding compounds
JP7427286B2 (en) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド IL-2RβγC binding compound
IL293553A (en) * 2019-12-06 2022-08-01 Theratechnologies Inc Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
AU2021219847A1 (en) * 2020-02-12 2022-10-13 Massachusetts Institute Of Technology Field deployable CRISPR-Cas diagnostics and methods of use thereof
US11453907B2 (en) 2020-03-23 2022-09-27 The Broad Institute, Inc. Crispr effector system based coronavirus diagnostics
WO2022026534A1 (en) * 2020-07-28 2022-02-03 Kansas State University Research Foundation Sars-cov-2 immunogenic compositions and methods for protecting against sars-cov-2 clinical signs
CA3197344A1 (en) * 2020-11-04 2022-05-12 William J. Dower Il-2r.beta.yc binding compounds and uses thereof
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2025017062A1 (en) * 2023-07-18 2025-01-23 Intervet International B.V. New type of streptococcus agalactiae serotype ia bacterium and vaccines thereof
WO2025151408A1 (en) * 2024-01-08 2025-07-17 Denali Therapeutics Inc. Compositions and methods for modulating tau expression
WO2025250877A1 (en) * 2024-05-31 2025-12-04 Saliogen Therapeutics, Inc. Mobile genetic elements from myotis myotis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006736A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2002092818A2 (en) * 2001-04-26 2002-11-21 Institut Pasteur Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
GB9921125D0 (en) * 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
JP5116971B2 (en) * 2002-10-15 2013-01-09 インターセル アーゲー Nucleic acid encoding an adhesion factor for group B streptococci, an adhesion factor for group B streptococci, and uses thereof
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006736A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2002092818A2 (en) * 2001-04-26 2002-11-21 Institut Pasteur Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 2 July 2002 (2002-07-02), "Streptococcus polypeptide SEQ ID NO 9444.", XP002397445, retrieved from EBI accession no. GSP:ABP30134 Database accession no. ABP30134 *
DATABASE Geneseq [online] 24 February 2005 (2005-02-24), "Streptococcus agalactiae protein, SEQ ID 2383.", XP002397448, retrieved from EBI accession no. GSP:ADV81242 Database accession no. ADV81242 *
DATABASE Geneseq [online] 30 May 2000 (2000-05-30), "Group B Streptococcus protein sequence SEQ ID NO:49.", XP002397447, retrieved from EBI accession no. GSP:AAY91320 Database accession no. AAY91320 *
DATABASE JPO Proteins [online] 17 July 2003 (2003-07-17), "Nucleic acid and protein originating in group B Streptococcus.", XP002397446, retrieved from EBI accession no. JPOP:BD629260 Database accession no. BD629260 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US9102741B2 (en) 2007-09-12 2015-08-11 Novartis Ag GAS57 mutant antigens and GAS57 antibodies

Also Published As

Publication number Publication date
MX2007007033A (en) 2007-08-03
AU2005319174A1 (en) 2006-06-29
IL183830A0 (en) 2007-10-31
JP2008525033A (en) 2008-07-17
WO2006069200A2 (en) 2006-06-29
US20090104218A1 (en) 2009-04-23
CA2591510A1 (en) 2006-06-29
EP1828231A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2006069200A3 (en) Group b streptococcus
WO2007076132A3 (en) Compositions comprising oriented, immobilized macromolecules and methods for their preparation
IL210485A (en) Isolated antibody or a functional protein, process for its preparation, pharmaceutical composition comprising the same and isolated nucleic acid encoding said antibody or functional protein
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2008143679A9 (en) Nucleic acids and proteins and methods for making and using them
WO2005118806A3 (en) METHODS AND COMPOSITIONS INVOLVING MicroRNA
ZA200706254B (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2008054676A3 (en) Medical devices and methods of using the same
IL196426A0 (en) Microparticulates based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
ZA200700397B (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2010051056A3 (en) ANTI-FcεRI POLYPEPTIDES AND THEIR USES
WO2007117763A3 (en) Methods and compositions for targeting relt
WO2008054595A3 (en) Drug controlled molecular tags
WO2007007325A3 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof
WO2005042566A3 (en) Antiangiogenicpeptides for treating or preventing endometriosis
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2006047728A3 (en) Bmp gene and fusion protein
WO2006091847A3 (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
WO2007102946A3 (en) Crystalline polypeptides
WO2007077464A3 (en) Chicken virus vaccine and diagnostic
WO2006089209A3 (en) Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2006060484A3 (en) Tuberculosis nucleic acids, polypeptides and immunogenic compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580044265.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 555934

Country of ref document: NZ

Ref document number: 2005319174

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 183830

Country of ref document: IL

Ref document number: 2005857170

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007033

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2591510

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2005319174

Country of ref document: AU

Date of ref document: 20051221

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007548453

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2701/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11793435

Country of ref document: US